This technology is a simple, rapid, and highly versatile sensitive assay for the detection and quantification of genomic signatures introduced by marker-free precision genome editing or resulting from genetic variation in cell population and animal models.
Recent advances in precision genome editing has spurred a revolution in molecular biology by enabling the introduction of precise genomic changes. Precision genome editing using CRISPR-mediated HDR, base editing or prime editing allow the correction and modeling of desired genomic bases, such as base transitions and transversions, small insertion and deletion mutations. However, the editing efficiency is highly variable, and the rate of incorporation must be determined experimentally. There is a need for assays that can track and quantify CRISPR-mediated precise edits independently of the mutation type and the genomic locus in a marker-free, rapid, cost-effective and simple yet highly sensitive manner.
This technology is a programmable assay that quantifies CRISPR-mediated precise genomic changes, including base substitutions and small insertions and deletions through the capture of targeted dinucleotide signatures. This technology uses a common set of adaptors to identify genomic changes, independently from the genomic locus or mutation type. This technology accurately quantifies marker-free genomic variants introduced by CRISPR-dependent HDR, base editing or prime editing in cellular and animal models, and the presence of oncogenic mutations in cancer mouse models and human cancer patient samples. The technology is a simple, but highly sensitive method for quantifying CRISPR-mediated genomic changes, and can facilitate tracking and validation of CRISPR-mediated genome editing in research and clinical fields.
Pierre Billon, PhD
IR CU18348
Licensing Contact: Cynthia Lang